المؤلفون: Shah, R. J., Wickersham, N., Lederer, D. J., Palmer, S. M., Cantu, E., Diamond, J. M., Kawut, S. M., Lama, V. N., Bhorade, S., Crespo, M., Demissie, E., Sonett, J., Wille, K., Orens, J., Weinacker, A., Shah, P., Arcasoy, S., Wilkes, D. S., Christie, J. D., Ware, L. B.

مصطلحات موضوعية: Lung Transplantation, Primary Graft Dysfunction, CC‐16, Acute Lung Injury, Biomarkers, Medicine (General), Health Sciences

وصف الملف: application/pdf

العلاقة: Shah, R. J.; Wickersham, N.; Lederer, D. J.; Palmer, S. M.; Cantu, E.; Diamond, J. M.; Kawut, S. M.; Lama, V. N.; Bhorade, S.; Crespo, M.; Demissie, E.; Sonett, J.; Wille, K.; Orens, J.; Weinacker, A.; Shah, P.; Arcasoy, S.; Wilkes, D. S.; Christie, J. D.; Ware, L. B. (2014). "Preoperative Plasma Club (Clara) Cell Secretory Protein Levels Are Associated With Primary Graft Dysfunction After Lung Transplantation." American Journal of Transplantation 14(2): 446-452.; https://hdl.handle.net/2027.42/102697Test; American Journal of Transplantation; Christie JD, Kotloff RM, Ahya VN, et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171: 1312 – 1316.; Christie JD, Bavaria JE, Palevsky HI, et al. Primary graft failure following lung transplantation. Chest 1998; 114: 51 – 60.; Covarrubias M, Ware LB, Kawut SM, et al. Plasma intercellular adhesion molecule‐1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7: 2573 – 2578.; Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124: 1232 – 1241.; Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24: 1454 – 1459.; Panwar R, Venkatesh B, Kruger P, et al. Plasma protein C levels in immunocompromised septic patients are significantly lower than immunocompetent septic patients: A prospective cohort study. J Hematol Oncol 2009; 2: 43.; Jorens PG, Sibille Y, Goulding NJ, et al. Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Eur Respir J 1995; 8: 1647 – 1653.; Seam N, Meduri GU, Wang H, et al. Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med 2012; 40: 495 – 501.; Pires‐Neto RC, Morales MMB, Lancas T, et al. Expression of acute‐phase cytokines, surfactant proteins, and epithelial apoptosis in small airways of human acute respiratory distress syndrome. J Crit Care 2013; 28: 111.e9 – 111.e15.; Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. J Am Med Assoc 2013; 309: 2353 – 2361.; Sims MW, Beers MF, Ahya VN, et al. Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis. Chest 2011; 140: 489 – 496.; Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest 2009; 135: 1440 – 1447.; Lesur O, Langevin S, Berthiaume Y, et al. Outcome value of Clara cell protein in serum of patients with acute respiratory distress syndrome. Intensive Care Med 2006; 32: 1167 – 1174.; Janssen R, Sato H, Grutters JC, et al. Study of Clara cell 16, KL‐6, and surfactant protein‐D in serum as disease markers in pulmonary sarcoidosis. Chest 2003; 124: 2119 – 2125.; Broeckaert F, Clippe A, Knoops B, Hermans C, Bernard A. Clara cell secretory protein (CC16): Features as a peripheral lung biomarker. Ann N Y Acad Sci 2000; 923: 68 – 77.; Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ 2009; 338: 157 – 160.; Shah RJ, Diamond JM, Cantu E, et al. Use of a simple prediction model improves pre‐transplant risk stratification for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187: A3773.; Maldonado G, Greenland S. Simulation study of confounder‐selection strategies. Am J Epidemiol 1993; 138: 923 – 936.; Lederer DJ, Kawut SM, Wickersham N, et al. Obesity and primary graft dysfunction after lung transplantation: The Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 2011; 184: 1055 – 1061.; Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28: 964 – 974.; Hermans C, Petrek M, Kolek V, et al. Serum Clara cell protein (CC16), a marker of the integrity of the air‐blood barrier in sarcoidosis. Eur Respir J 2001; 18: 507 – 514.; Hoffman SA, Wang L, Shah CV, et al. Plasma cytokines and chemokines in primary graft dysfunction post‐lung transplantation. Am J Transplant 2009; 9: 389 – 396.; Lee JC, Christie JD. Primary graft dysfunction. Proc Am Thorac Soc 2009; 6: 39 – 46.; Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364: 1431 – 1440.; Department of Health and Human Services HRaSA, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA. 2012. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Transplant Data 1994–2012. 2012.; Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187: 527 – 534.; Shah RJ, Bellamy SL, Localio AR, et al. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. J Heart Lung Transplant 2012; 31: 942 – 949.; Diamond JM, Kawut SM, Lederer DJ, et al. Elevated plasma Clara cell secretory protein concentration is associated with high‐grade primary graft dysfunction. Am J Transplant 2011; 11: 561 – 567.; Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180: 1010 – 1015.; Christie JD, Robinson N, Ware LB, et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007; 175: 69 – 74.

الإتاحة: https://doi.org/10.1111/ajt.12541Test
https://hdl.handle.net/2027.42/102697Test

المؤلفون: Diamond, J. M., Lederer, D. J., Kawut, S. M., Lee, J., Ahya, V. N., Bellamy, Scarlett, Palmer, S. M., Lama, V. N., Bhorade, S., Crespo, M., Demissie, E., Sonett, J., Wille, K., Orens, J., Shah, P. D., Weinacker, A., Weill, D., Kohl, B. A., Deutschman, C. C., Arcasoy, S., Shah, A. S., Belperio, J. A., Wilkes, D., Reynolds, J. M., Ware, L. B., Christie, Jason D.

المساهمون: Division of Pulmonary, Allergy, and Critical Care Medicine, University of Michigan, Ann Arbor, MI, Pulmonary, Allergy, and Critical Care Division, Center for Clinical Epidemiology and Biostatistics, Penn Cardiovascular Institute, Department of Anesthesia and Critical Care, University of Pennsylvania School of Medicine, Philadelphia, PA, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University, Raleigh‐Durham, NC, Division of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL, Division of Pulmonary, Allergy, and Critical Care, University of Pittsburgh, Pittsburgh, PA, Division of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Johns Hopkins University Hospital, Baltimore, MD, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, Division of Pulmonary and Critical Care Medicine, Stanford University, Palo Alto, CA, Department of Surgery, Johns Hopkins University Hospital, Baltimore, MD, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, Division of Pulmonary, Allergy, Critical Care, and Occupational Medicine, Indiana University School of Medicine, Indianapolis, IN

مصطلحات موضوعية: Idiopathic Pulmonary Fibrosis, Long Pentraxin‐3, Lung Transplantation, Primary Graft Dysfunction, Medicine (General), Health Sciences

وصف الملف: application/pdf

العلاقة: Diamond, J. M.; Lederer, D. J.; Kawut, S. M.; Lee, J.; Ahya, V. N.; Bellamy, S.; Palmer, S. M.; Lama, V. N.; Bhorade, S.; Crespo, M.; Demissie, E.; Sonett, J.; Wille, K.; Orens, J.; Shah, P. D.; Weinacker, A.; Weill, D.; Kohl, B. A.; Deutschman, C. C.; Arcasoy, S.; Shah, A. S.; Belperio, J. A.; Wilkes, D.; Reynolds, J. M.; Ware, L. B.; Christie, J. D. (2011). "Elevated Plasma Long Pentraxin‐3 Levels and Primary Graft Dysfunction After Lung Transplantation for Idiopathic Pulmonary Fibrosis." American Journal of Transplantation 11(11).; https://hdl.handle.net/2027.42/88085Test; American Journal of Transplantation; Iwata T, Philipovskiy A, Fisher AJ, et al. Anti‐type V collagen humoral immunity in lung transplant primary graft dysfunction. J Immunol 2008; 181: 5738 – 5747.; Moreno I, Vicente R, Ramos F, Vicente JL, Barbera M. Determination of interleukin‐6 in lung transplantation: Association with primary graft dysfunction. Transplant Proc 2007; 39: 2425 – 2426.; Diamond JM, Christie JD. The contribution of airway and lung tissue ischemia to primary graft dysfunction. Curr Opin Organ Transplant 2010; 15: 552 – 557.; Millington TM, Madsen JC. Innate immunity and cardiac allograft rejection. Kidney Int 2010; 78 ( Suppl 119 ): S18 – S21.; Millington TM, Madsen JC. Innate immunity in heart transplantation. Curr Opin Organ Transplant 2009; 14: 571 – 576.; Kosieradzki M, Rowinski W. Ischemia/reperfusion injury in kidney transplantation: Mechanisms and prevention. Transplant Proc 2008; 40: 3279 – 3288.; Uchida Y, Ke B, Freitas MC, et al. T‐cell immunoglobulin mucin‐3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4‐dependent manner. Gastroenterology 2010; 139: 2195 – 2206.; Hoffman SA, Wang L, Shah CV, et al. Plasma cytokines and chemokines in primary graft dysfunction post‐lung transplantation. Am J Transplant 2009; 9: 389 – 396.; Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636 – 641.; Han B, Haitsma JJ, Zhang Y, et al. Long pentraxin PTX3 deficiency worsens LPS‐induced acute lung injury. Intensive Care Med 2011; 37: 334 – 342.; Mauri T, Coppadoro A, Bellani G, et al. Pentraxin 3 in acute respiratory distress syndrome: An early marker of severity. Crit Care Med 2008; 36: 2302 – 2308.; Covarrubias M, Ware LB, Kawut SM, et al. Plasma intercellular adhesion molecule‐1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7: 2573 – 2578.; Christie JD, Bellamy S, Ware LB, et al. Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2010; 29: 1231 – 1239.; Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180: 1010 – 1015.; Diamond JM, Kawut SM, Lederer DJ, et al. Elevated plasma clara cell secretory protein concentration is associated with high‐grade primary graft dysfunction. Am J Transplant 2011; 11: 561 – 567.; Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124: 1232 – 1241.; Kuntz CL, Hadjiliadis D, Ahya VN, et al. Risk factors for early primary graft dysfunction after lung transplantation: A registry study. Clin Transplant 2009; 23; 819 – 830.; Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001; 29: 1404 – 1407.; Ortega‐Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM. The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum 2009; 39: 38 – 54.; Weill D, Dey GC, Hicks RA, et al. A positive donor gram stain does not predict outcome following lung transplantation. J Heart Lung Transplant 2002; 21: 555 – 558.

الإتاحة: https://doi.org/10.1111/j.1600-6143.2011.03702.xTest
https://hdl.handle.net/2027.42/88085Test

المؤلفون: Hoffman, S. A., Wang, L., Shah, Chirag V., Ahya, V. N., Pochettino, A., Olthoff, Kim M., Shaked, Abraham, Wille, K., Lama, V. N., Milstone, A., Ware, L. B., Orens, J., Weinacker, A., Demissie, E., Bellamy, Scarlett, Kawut, S. M., Hancock, W. W., Christie, Jason D.

المساهمون: Division of Pulmonary, Allergy, and Critical Care Medicine, University of Michigan, Ann Arbor, MI, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, Division of Transplantation Immunology, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, Department of Biostatistics and Epidemiology, University of Pennsylvania School of Medicine, Philadelphia, PA, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA, Division of Pulmonary and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, Division of Pulmonary and Critical Care Medicine, Vanderbilt University, Nashville, TN, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University Hospital, Baltimore, MD, Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY, Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY

مصطلحات موضوعية: Chemokines, Cytokines, Lung Transplantation, Primary Graft Dysfunction, Reperfusion Injury, Medicine (General), Health Sciences

وصف الملف: 223225 bytes; 3109 bytes; application/pdf; text/plain

العلاقة: Hoffman, S. A.; Wang, L.; Shah, C. V.; Ahya, V. N.; Pochettino, A.; Olthoff, K.; Shaked, A.; Wille, K.; Lama, V. N.; Milstone, A.; Ware, L. B.; Orens, J.; Weinacker, A.; Demissie, E.; Bellamy, S.; Kawut, S. M.; Hancock, W. W.; Christie, J. D. (2009). "Plasma Cytokines and Chemokines in Primary Graft Dysfunction Post-Lung Transplantation." American Journal of Transplantation 9(2): 389-396.; https://hdl.handle.net/2027.42/72208Test; http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19120076&dopt=citationTest; American Journal of Transplantation; Christie JD, Bavaria JE, Palevsky HI et al. Primary graft failure following lung transplantation. Chest 1998; 114: 51 – 60.; King RC, Binns OA, Rodriguez F et al. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg 2000; 69: 1681 – 1685.; Christie JD, Kotloff RM, Pochettino A et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124: 1232 – 1241.; Arcasoy SM, Kotloff RM. Lung transplantation. N Engl J Med 1999; 340: 1081 – 1091.; De Perrot M, Sekine Y, Fischer S et al. Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med 2002; 165: 211 – 215.; Christie JD, Sager JS, Kimmel SE et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127: 161 – 165.; Arcasoy SM, Fisher A, Hachem RR, Scavuzzo M, Ware LB. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: Predictors and outcomes. J Heart Lung Transplant 2005; 24: 1483 – 1488.; Christie JD, Kotloff RM, Ahya VN et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171: 1312 – 1316.; Christie JD, Van Raemdonck D, de Perrot M et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part I: Introduction and methods. J Heart Lung Transplant 2005; 24: 1451 – 1453.; Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24: 1454 – 1459.; de Perrot M, Bonser RS, Dark J et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: Donor-related risk factors and markers. J Heart Lung Transplant 2005; 24: 1460 – 1467.; de Perrot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 2003; 167: 490 – 511.; Barr ML, Kawut SM, Whelan TP et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part IV: Recipient-related risk factors and markers. J Heart Lung Transplant 2005; 24: 1468 – 1482.; Serrick C, Adoumie R, Giaid A, Shennib H. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation 1994; 58: 1158 – 1162.; Naidu BV, Farivar AS, Woolley SM, Grainger D, Verrier ED, Mulligan MS. Novel broad-spectrum chemokine inhibitor protects against lung ischemia-reperfusion injury. J Heart Lung Transplant 2004; 23: 128 – 134.; Wacholder S. Design issues in case control studies. Stat Methods Med Res 1995; 4: 293 – 309.; Christie JD, Robinson N, Ware LB et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007; 175: 69 – 74.; Covarrubias M, Ware LB, Kawut SM et al. Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7: 2573 – 2578.; Frangogiannis NG. The role of the chemokines in myocardial ischemia and reperfusion. Curr Vasc Pharmacol 2004; 2: 163 – 174.; Tatapudi RR, Muthukumar T, Dadhania D et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65: 2390 – 2397.; Melter M, Exeni A, Reinders ME et al. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104: 2558 – 2564.; Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193: 975 – 980.; Hancock WW, Lu B, Gao W et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515 – 1520.; Mathur A, Baz M, Staples ED et al. Cytokine profile after lung transplantation: Correlation with allograft injury. Ann Thorac Surg 2006; 81: 1844 – 1849; discussion 1849–1850.

الإتاحة: https://doi.org/10.1111/j.1600-6143.2008.02497.xTest
https://hdl.handle.net/2027.42/72208Test
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19120076&dopt=citationTest